NEW YORK (GenomeWeb News) – Transgenomic said today it has entered into a laboratory services partnership agreement with the Guangzhou Family Planning Center in China that it will use to provide pharmacogenomic analysis services to pharmaceutical companies seeking to perform clinical trials in China.
Transgenomic said it has already equipped the Guangzhou facility with the technology necessary to provide pharmacogenomics services.
Transgenomic President and CEO Craig Tuttle said the agreement provides the firm with the lab it needs to open “significant new clinical testing opportunities for us.”